about
Renal comorbidity after solid organ and stem cell transplantationGenome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility lociDense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis.Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9Criteria Used in Clinical Practice to Guide Immunosuppressive Treatment in Patients with Primary Sclerosing Cholangitis.Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci.Compartment-specific distribution of human intestinal innate lymphoid cells is altered in HIV patients under effective therapy.Differential serum levels of eosinophilic eotaxins in primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis.Medical and endoscopic therapy of primary sclerosing cholangitis.Gadoxetate disodium in patients with primary sclerosing cholangitis: an analysis of hepatobiliary contrast excretion.Risk estimation for biliary tract cancer: Development and validation of a prognostic score.Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.No Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis.Genome-wide association analysis in primary sclerosing cholangitis.Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis.Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis.Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease.Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A retrospective multicenter analysis.[Complications after Percutaneous Endoscopic Gastrostomy Tube Placement - A Retrospective Analysis].A pocket guide to identify patients at risk for chronic kidney disease after liver transplantation.[Biliary diseases - new insights and developments].Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis.Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany.Effects of norepinephrine and cardiotrophin-1 on phospholipase D activity and incorporation of myristic acid into phosphatidylcholine in rat heart.Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders.The introduction of MELD-based organ allocation impacts 3-month survival after liver transplantation by influencing pretransplant patient characteristics.Antineutrophil cytoplasmic antibodies in bile are associated with disease activity in primary sclerosing cholangitis.Prediction of survival after liver transplantation by pre-transplant parameters.Routine bile collection for microbiological analysis during cholangiography and its impact on the management of cholangitis.Screening colonoscopy in liver transplant candidates: risks and findings.Primär sklerosierende Cholangitis - Herausforderungen gemeinsam meisternPercutaneous transgastral biliodigestive diversion as treatment option for benign recurrent intrahepatic cholestasisMeasurement of IgG4 in bile: a new approach for the diagnosis of IgG4-associated cholangiopathyPeripapillary duodenal varices as a rare cause of severe bleeding in a patient with no other signs of portal hypertension--successful endoscopic treatment with cyanoacrylate injectionEducation and imaging. Gastrointestinal: PEG feeding tube migration into the colon; a late manifestationFerritin and liver allocation? Impact on mortality not only on the waiting list but also after orthotopic liver transplantation should be consideredValue of the preoperative SOFT-score, P-SOFT-score, SALT-score and labMELD-score for the prediction of short-term patient and graft survival of high-risk liver transplant recipients with a pre-transplant labMELD-score ≥30Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany--limitations of the 'sickest first'-conceptAsparagus and jejunal-through-PEG: an unhappy encounter in intrajejunal levodopa infusion therapy
P50
Q26850625-BB100B1C-8F64-4BDC-95BA-BB5AE8CA69AEQ28943462-5D1051C5-724E-4B22-9B5B-56080F41098DQ28943478-1665852E-D084-48DD-BBF3-A60854962F50Q30416155-095388B8-B17B-4398-8A22-324D635FD50CQ35062213-A1D7F287-B803-4785-A508-A6B8F94A2212Q35816345-ED6F44CA-9C15-43CF-89CB-33CAEFCA5361Q36101099-E48D190D-303B-431D-906A-EC369E9F1D0EQ36372127-A4A9E295-3933-4C12-A9AA-EDCABE7A688FQ37617640-F8E98232-6273-4324-90F6-E0AD3BB8C29BQ37960967-00AC7F35-FCA4-487D-9074-09B5BA0F4BD4Q38219784-18E11BA9-6D08-4BE8-95DC-7EDADDFD5AC1Q38684712-F0451AC9-AB59-4244-9316-24D4D7056D33Q38919832-04BFF8FF-FA46-477B-8E29-E3CB42A2B5BEQ39493270-7DF6B08D-93FE-4C07-8891-586B13B9F83FQ39769745-A57620E5-60AF-415C-8809-7784BD60A90EQ39775602-3888850B-DA7C-4D08-9A6E-BC331653256FQ40094085-4A9A18E0-95D2-4DB4-B12C-79C37C5E0DBBQ40418336-77AC7E87-E69B-462B-8221-464A6A3A43E9Q40465417-6B0F679C-B6C1-4D7A-86B0-414723E4884CQ41498562-47E1163B-E214-4FB4-8B99-7478ED204241Q41592889-F7977D04-AE77-46BC-8BCD-72C09B859003Q43562372-B91E17FC-7C9E-4D5E-B20D-51FEA9E213B3Q43669264-4F4CB45B-B3C2-47EA-BD7E-6B936FB93178Q44503780-D8E61EA1-C24A-439F-BD2C-78FFA4811FA4Q44991900-D5500D2F-E43C-4864-98E1-5C8825A90C72Q45899921-8A7BB239-38E1-4819-84C0-877F833C33FEQ45924990-623320D2-50CF-41DC-A504-3A61F3FEF2DBQ45971399-114C47A8-CC76-4146-B6FD-0CB533E0BC6FQ46526869-FF9B46CA-0F59-4914-A602-ACF98DB50ECAQ51767427-25E9899B-584F-48C0-820F-FC7E4C97853EQ53789518-5375C89B-BA23-4172-8839-C4B15F251C7BQ58130894-D4A0E7AA-0476-408B-B679-64D10D9F4B81Q58588961-73E08C29-E16B-4778-95B1-38824A0EA627Q83133934-C6083BF9-9661-4CDF-88A4-5246B7D9785AQ84071377-320243F3-0DDD-43D2-B97D-DBFB4374120CQ84409098-8D974619-53B4-4A0F-A107-5517BB4AF396Q84476615-36E5AA61-8929-42B8-BFEF-282A1CDA429CQ84488919-2450ECEF-9742-48CB-B1D2-CEF5B9211283Q84985422-40AE6A00-457F-4D85-B73C-A2937F5B1AC1Q85174162-5D70C751-DAA3-4363-B946-A9811FE0E6E4
P50
description
gastroenteroloog
@nl
hulumtues
@sq
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Tobias J. Weismüller
@ast
Tobias J. Weismüller
@en
Tobias J. Weismüller
@es
Tobias J. Weismüller
@nl
Tobias J. Weismüller
@sl
type
label
Tobias J. Weismüller
@ast
Tobias J. Weismüller
@en
Tobias J. Weismüller
@es
Tobias J. Weismüller
@nl
Tobias J. Weismüller
@sl
altLabel
Tobias J Weismüller
@en
prefLabel
Tobias J. Weismüller
@ast
Tobias J. Weismüller
@en
Tobias J. Weismüller
@es
Tobias J. Weismüller
@nl
Tobias J. Weismüller
@sl
P214
P227
P1153
23490921300
P21
P213
0000 0000 1680 6165
P214
P227
P31
P496
0000-0001-9736-1483
P569
1975-01-01T00:00:00Z
P734
P735
P7859
viaf-52763938